Rumeyza Kazancioglu, Meltem Gursu. (2015) New options in the treatment of autosomal dominant polycystic kidney disease. Renal Failure 37 , 535-541 /Rumeyza Kazancioglu, Meltem Gursu. (2015) New options in the treatment of autosomal dominant polycystic kidney disease. Renal Failure , 1-7 /...
International Journal of Nephrology and Renovascular Disease Dovepress open access to scientific and medical research Open Access Full Text Article Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment REVIEW Christian R Halvorson1 Matthew S Bremmer1 Stephen C Jacobs1 1Department...
or adults who have chronic kidney disease or end stage renal disease (ESRD), with cysts most likely in people who are ondialysis. Unlike other types of PKD, the condition is caused by CKD or ESRD, not inherited. Risk f ACKD increases with the number of years on dialysis treatment. ...
Cystic kidney diseases are among the most common causes of end stage renal disease both in children and adults. The two main forms of genetic cystic kidney disorders are Autosomal Dominant and Autosomal Recessive Polycystic Kidney Disease (ADPKD and ARPKD). While ADPKD is a common disorder mainly ...
Palladio is initially developing its lead drug, lixivaptan, for Polycystic Kidney Disease, an orphan kidney disease for which there are limited treatment options. Palladio Biosciences Names Martin Chief Executive Officer The presentation outlines the critical issues facing millions of patients with progressi...
Polycystic Kidney Disease (also known as Polycystic Kidney Syndrome) (PKD) is a progressive, genetic disorder of the kidneys. It occurs in humans and other organisms. PKD is characterized by the presence of multiple cysts (hence, "polycystic") in both kidneys. The disease can also damage the...
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetic cause of end-stage kidney failure with limited treatment options. The realization that miRNA upregulation, and thus its gain-of-function, can drive the progression of ADPKD has raised the possibility that anti-miRs ...
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease with few treatment options other than renal replacement therapy. p21, a cyclin kinase inhibitor which has pleiotropic effects on the cell cycle, in many cases acts to suppress cell cycle progression and to prevent apopt...
We look forward to advancing AP303 to improve future treatment options for patients in need.”1 References 1. PR Newswire. Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease...
MRI: Not routine; helpful in distinguishing renal cell carcinoma from simple cysts; criterion standard to help determine renal volume for clinical trials when testing drugs for ADPKD; best imaging tool for monitoring kidney size after treatment, as an indication of disease progress. ...